ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad

Shares of ImmunityBio plunged 26% after the FDA issued a March 13 warning letter saying a TV ad and podcast promoting Anktiva were false or misleading and ordered the company to cease the materials and respond within 15 working days. Anktiva was approved in April 2024; the company reported $113M in global Anktiva sales for 2025 and analysts expect $217.6M for the current year (LSEG). Management said it will review and respond within the requested timeframe, and Piper Sandler maintains its revenue forecast believing the company can comply.

Analysis

A removal of a major direct-to-consumer marketing channel for a recently launched oncology drug materially changes the adoption curve: expect a meaningful pullback in new patient starts for 4–12 weeks while the company rebuilds compliant messaging. For a nascent revenue stream, lost new starts compound because oncology prescribing has a long tail—each monthly shortfall reduces lifetime patient treatment revenue and can compress FY+1 consensus by a high-single-digit to low-double-digit percent depending on payor uptake.

Regulatory escalation here raises the bar for future label expansion and promotional language; anticipate slower commercial access (restricted formularies, more prior authorization) and a higher probability of sponsor-funded confirmatory post-approval studies being demanded. Management credibility has been impaired with both investors and prescribers, increasing the cost of capital for any near-term bridge financings or partnership negotiations and opening the door to adverse legal/SEC inquiries that can take quarters to resolve.

Tradeable window: downside pressure should concentrate in the next 1–3 months as the company responds and the market re-prices adoption curves; medium-term (3–12 months) risk centers on issuer responses, payer feedback, and any formal FDA enforcement actions that affect labeling or distribution. Conversely, a rapid, well-documented remediation plus release of supporting efficacy data would be a catalyst for a sharp relief rally.

Position sizing should be conservative: reputational events are binary and can overshoot. Monitor four near-term checkpoints—company regulatory response, commercial inventory/marketing cadence, payer coverage notes, and any litigation filings—to update conviction and exit levels.

Key Decisions for Investors

• Short IBRX equity (target -40% over 1–3 months) with a hard stop at +25% adverse move; use 3–6 month put options (buy puts 25–35% OTM if implied vol is reasonable) to cap downside and target 3:1 reward-to-risk.
• Pair trade: short IBRX / long MRK (or BMY) 1:1 size to remain oncology-beta neutral; entry now, target capture of relative move (IBRX underperformance vs MRK/BMY by 30–50% within 3 months), stop if spread narrows by 15%.
• Event-driven options: buy 6-month IBRX puts and sell 1–2 month puts to finance theta if IV term structure is steep; reduce net Vega exposure and target 2–3x payoff if adverse regulatory outcome occurs.
• Conservative defensive long: buy MRK (ticker MRK) exposure for 6–12 months as a play on durable immuno-oncology demand and to hedge sector rotation away from smaller, high-regulatory-risk names.